Equities research analysts expect that Dexcom (NASDAQ:DXCM) will report earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Eleven analysts have made estimates for Dexcom’s earnings, with estimates ranging from ($0.43) to ($0.10). Dexcom posted earnings of ($0.49) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 34.7%. The company is scheduled to announce its next quarterly earnings results after the market closes on Wednesday, May 2nd.
On average, analysts expect that Dexcom will report full year earnings of ($0.56) per share for the current financial year, with EPS estimates ranging from ($0.81) to ($0.27). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.24) per share, with EPS estimates ranging from ($0.85) to $0.02. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Dexcom.
Dexcom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.07. The business had revenue of $221.00 million during the quarter, compared to analyst estimates of $217.82 million. Dexcom had a negative return on equity of 13.99% and a negative net margin of 6.99%.
In other Dexcom news, insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total transaction of $568,600.00. Following the completion of the sale, the insider now directly owns 484,559 shares in the company, valued at approximately $27,552,024.74. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $54.67, for a total value of $89,385.45. Following the sale, the executive vice president now owns 65,049 shares of the company’s stock, valued at $3,556,228.83. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,854 shares of company stock valued at $2,141,081. 1.70% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the business. American International Group Inc. purchased a new stake in Dexcom during the 4th quarter worth approximately $116,000. Thompson Davis & CO. Inc. purchased a new stake in Dexcom during the 4th quarter worth approximately $137,000. Zions Bancorporation increased its stake in Dexcom by 36,222.2% during the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after buying an additional 3,260 shares in the last quarter. Marco Investment Management LLC purchased a new stake in Dexcom during the 4th quarter worth approximately $201,000. Finally, D.A. Davidson & CO. purchased a new stake in Dexcom during the 4th quarter worth approximately $208,000.
NASDAQ DXCM opened at $70.15 on Monday. The stock has a market cap of $6,102.84, a price-to-earnings ratio of -120.95 and a beta of -0.01. Dexcom has a fifty-two week low of $42.62 and a fifty-two week high of $81.91. The company has a quick ratio of 5.04, a current ratio of 5.36 and a debt-to-equity ratio of 0.78.
WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3342105/brokerages-expect-dexcom-dxcm-will-post-earnings-of-0-32-per-share.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.